palmitoylethanolamide.com.au
HomeResearchYe 2020

PPARα-Dependent Effects of Palmitoylethanolamide Against Retinal Neovascularization and Fibrosis

Ye S, Chen Q, Jiang N, Liang X, Li J, Zong R, Huang C, Qiu Y, Ma JX, Liu Z. Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):15.

Laboratory studyOther animals

Design
Laboratory study
Subjects
A rat Muller cell line (rMC-1), a mouse model of oxygen-induced retinopathy (OIR), and very-low-density lipoprotein receptor (VLDLR) knockout mice
Dose used in the study
PEA given by intraperitoneal injection or oral administration; exact dose not stated in the abstract
Duration
Not stated in the abstract
What was measured
Inflammation and profibrotic markers by western blot, and GFAP and PPAR-alpha by RT-PCR and western blot, in retina and Muller cells

What the authors reported

Profibrotic changes were present in OIR and VLDLR-knockout retinas. PEA reduced inflammation, inhibited neovascularization and suppressed profibrotic changes and Muller gliosis in both models, and in rMC-1 cells. PPAR-alpha mRNA and protein rose with PEA treatment, and the effects of PEA were lost in PPAR-alpha knockout OIR mice.

Limits of this study

A cell-line and animal-model study; it cannot show effect in people. The authors declare no financial or proprietary interest.

Source

PubMed 32298438 · doi:10.1167/iovs.61.4.15

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.